Evolus, Inc. (NASDAQ:EOLS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Evolus, Inc. (NASDAQ:EOLS) have been assigned an average rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $20.80.

EOLS has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. Needham & Company LLC restated a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Evolus in a research report on Friday. Mizuho dropped their target price on shares of Evolus from $20.00 to $19.00 and set an “outperform” rating on the stock in a research report on Monday, December 1st. Finally, Wall Street Zen upgraded shares of Evolus from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th.

Evolus Trading Down 1.6%

NASDAQ EOLS opened at $5.65 on Friday. The firm’s fifty day simple moving average is $6.80 and its two-hundred day simple moving average is $7.29. The firm has a market capitalization of $366.23 million, a P/E ratio of -6.14 and a beta of 0.91. Evolus has a 12-month low of $5.13 and a 12-month high of $17.12.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.05. The business had revenue of $68.97 million for the quarter, compared to analysts’ expectations of $91.23 million. As a group, sell-side analysts predict that Evolus will post -0.61 earnings per share for the current fiscal year.

Insider Transactions at Evolus

In related news, insider David Moatazedi sold 10,539 shares of the firm’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $7.15, for a total value of $75,353.85. Following the completion of the transaction, the insider owned 354,388 shares in the company, valued at $2,533,874.20. This trade represents a 2.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 5.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Manchester Capital Management LLC purchased a new position in shares of Evolus in the second quarter worth about $26,000. State of Alaska Department of Revenue acquired a new position in Evolus in the 3rd quarter worth approximately $26,000. Wexford Capital LP purchased a new position in Evolus during the 3rd quarter worth approximately $37,000. Tower Research Capital LLC TRC raised its position in Evolus by 340.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock worth $68,000 after buying an additional 5,691 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in Evolus during the 3rd quarter valued at approximately $48,000. 90.69% of the stock is owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.